Phio Pharmaceuticals Secures New South Korean Patent for Anti-Aging Compound

Phio Pharmaceuticals Corp., based in Marlborough, Massachusetts, announced a significant milestone in its skincare innovation efforts. The clinical-stage biotechnology company has been granted a new patent in South Korea for its groundbreaking INTASYL RXI-185 compound, which is engineered to combat photo-aging by targeting the MMP1 gene responsible for collagen degradation caused by UV exposure.

This patent is a key addition to Phio’s robust portfolio, which includes 81 issued patents, focusing predominantly on the INTASYL siRNA gene silencing technology. INTASYL RXI-185 represents Phio’s dedication to advancing treatments that not only enhance skin appearance by slowing aging effects like wrinkles and loss of elasticity but also complement the company’s ongoing skin cancer therapies.

CEO Robert Bitterman emphasized the importance of this patent, highlighting its alignment with Phio’s strategic focus on enhancing skin health through innovative, gene-based therapies.